临床与实验病理学杂志2019，Vol.35Issue(3)：268-273,6.DOI:10.13315/j.cnki.cjcep.2019.03.004
乳腺癌原发肿瘤和复发肿瘤间ER、PR和HER-2表达不一致及其对患者生存的影响
ER, PR and HER-2 discordances between primary and recurrent cancer and their impact on survival of breast cancer patient
摘要
Abstract
Purpose To assess the frequency of discordances in ER, PR and HER-2 status between primary and recurrent cancer and the impact of the discordance on breast cancer patient survival. Method Immunohistochemistry and/or fluorescent in situ hybridization was used to evaluate ER, PR and HER-2 status of primary and recurrent cancer in 62 breast cancer patients. The correlation between discordances in ER, PR and HER-2 receptors and clinicopathologic characteristics and patient survival was analyzed. Results Among 62 patients with breast recurrent cancer, discordance rate for ER, PR, and HER-2 was found in 6 (9.7％), 9 (14.5％) and 3 (4.8％) patients, respectively. During the follow-up period the ER-discordant cases had a poorer overall survival (median 29 months vs 44 months, P=0.021) and post-recurrence survival (median 6 months vs 15 months, P=0.027), compared with the concordant cases. No impact on overall survival or post-recurrence survival was observed for PR and HER-2 discordance when compared with the respective concordant cases (P> 0.05 for all).Conclusion Our results demonstrate an evident change regarding ER, PR and HER-2 between breast primary and recurrent cancer, and the ER unstable status in breast cancer suggust a worse prognosis.关键词
乳腺肿瘤/荷尔蒙受体/HER-2/不一致/生存Key words
breast neoplasm/hormone receptor/HER-2/discordance/survival分类
医药卫生引用本文复制引用
杨宇峰,庾建中,林思园,张利华,杨梅..乳腺癌原发肿瘤和复发肿瘤间ER、PR和HER-2表达不一致及其对患者生存的影响[J].临床与实验病理学杂志,2019,35(3):268-273,6.基金项目
广东省医学科研基金(2015105101078) （2015105101078）
